Observational Study of Immune Response to Hepatitis B Childhood Booster

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Oxford
ClinicalTrials.gov Identifier:
NCT00873652
First received: January 27, 2009
Last updated: May 7, 2013
Last verified: May 2013
  Purpose

The UK immunisation guidelines recommend that children immunised with an accelerated course of hepatitis B vaccine (i.e. vaccination at 0, 1, 2 and 12 months) receive an additional booster dose of vaccine in later childhood (usually at 3 1/2 years of age). The primary objective of this study is to to assess what proportion of these children have 'protective' concentrations (10mIU/ml) of hepatitis B specific antibodies before and after the booster dose of hepatitis B vaccine.


Condition Intervention
Healthy
Biological: Engerix B®, a recombinant hepatitis B vaccine

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: An Observational Study of Children Immunised in Infancy Against Hepatitis B Virus, Evaluating the Persistence of Immunity and the Immune Response to a Scheduled Booster Dose of Hepatitis B Vaccine

Resource links provided by NLM:


Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • The percentage of participants completing an accelerated course of hepatitis B vaccination with 10 IU/ml Hepatitis B surface antigen specific antibodies (antiHBs) before and after the 'pre−school' booster dose of Hepatitis B vaccine. [ Time Frame: immediately prior to vaccination and 4 weeks post vaccination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the percentage of participants who had serum antiHBs concentrations < 10 IU/ml at visit 1 who had a rise in serum antiHBs to 10 IU/ml at visit 2. [ Time Frame: immediately prior to vaccination and 4 weeks post-vaccination ] [ Designated as safety issue: No ]
  • To evaluate the percentage of participants who had serum antiHBs concentrations < 10 IU/ml at visit 1 who had a rise in serum antiHBs to 100 IU/ml at visit 2. [ Time Frame: immediately prior to vaccination and 4 weeks post-vaccination ] [ Designated as safety issue: No ]
  • To evaluate the serum antiHBs geometric mean concentrations (GMCs) at visit 1 and visit 2. [ Time Frame: immediately prior to vaccination and 4 weeks post-vaccination ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum


Enrollment: 28
Study Start Date: February 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: Engerix B®, a recombinant hepatitis B vaccine
    Single 0.5 ml dose intramuscularly into the deltoid muscle
    Other Name: Hepatitis B Vaccine (Recombinant)
Detailed Description:

This is an observational, open label study of children immunised in infancy against Hepatitis B virus (HBV),evaluating the persistence of immunity and the immune response to a scheduled booster dose of Hepatitis B vaccine.

Children eligible/overdue for their pre school HBV vaccine booster will be identified by reviewing clinical records at the John Radcliffe Hospital. The parents/legal guardians of these children will be written to and advised that their child should receive/ have received a booster dose of HBV vaccine. This letter will also inform parents/ legal guardians that they have the option of participating in this study looking at the persistence of HBV vaccine induced antibodies through early childhood and the response to a booster dose of HBV vaccine, and that this study will be conducted by the Oxford Vaccine Group in the participants' homes. Parents will be advised that if they do not wish to take part in this research study they should arrange to contact their GP to discuss whether their child requires a booster dose of hepatitis B vaccine.

For participants the study will consist of two visits at a four week interval(visit 1 and visit 2). If the parents/guardians then sign the consent form a medical and immunisation history will be taken and a medical examination will be undertaken if indicated. If no exclusion criteria are identified, the child will be enrolled in the study. A 6ml blood sample will be taken from the child and single booster dose of Hepatitis B vaccine will be administered.

For all children receiving the booster dose of vaccine and their GP, practice nurse and child health department will be informed. If the child is also due for their other pre−school booster vaccines (the 4 in 1 Diphtheria, tetanus, tetanus and polio vaccine, the combined Hib−MenC vaccine and the combined measles, mumps, rubella vaccine (MMR)) these will also be offered, but will not form part of the study assessment.

At the second visit following a confirmation of ongoing consent for the study the first eligibility for inclusion will be checked along with the occurrence of any serious adverse events, 6mls of blood will be drawn from the participant.

Blood samples will be used for antibody analysis by ELISA.

  Eligibility

Ages Eligible for Study:   41 Months to 7 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Children have been recorded as having commenced an accelerated course of HBV vaccine between the years 2000 and 2006

Criteria

Inclusion Criteria:

  • Parent/guardian is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 3 years 4 months or above.
  • Commenced Hepatitis B post exposure prophylaxis at birth.
  • Able (in the Investigators opinion) and willing to comply with all study requirements.
  • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion Criteria:

  • Parent/guardian is not willing or able to give informed consent for participation in the study.
  • The child is currently enrolled in any other interventional research study
  • History of a confirmed anaphylactic reaction to a previous dose of hepatitis B containing vaccine or a confirmed reaction to any component of the vaccine
  • Evidence of infection with HBV on previous blood tests.
  • Previous receipt of booster doses of HBV vaccine within the 2 years prior to study enrolment.
  • Significant renal or hepatic impairment.
  • Participant who is terminally ill.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient/participant at risk because of participation in the study, or may influence the result of the study, or the patient/participant's ability to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00873652

Locations
United Kingdom
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital
Oxford, Oxfordshire, United Kingdom, OX3 7LJ
Sponsors and Collaborators
University of Oxford
Investigators
Principal Investigator: Matthew D Snape, MBBS, FRCPCH Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ
  More Information

Publications:
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT00873652     History of Changes
Other Study ID Numbers: OVG 2008/5
Study First Received: January 27, 2009
Last Updated: May 7, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University of Oxford:
Hepatitis B vaccine
Booster dose
Persistence
Immune response
Healthy children

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on October 23, 2014